INC Research Expands Clinical Pharmacology Team To Support Early Phase Business Unit
Raleigh, N.C., – INC Research, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Beatrice Setnik, PhD, as Vice President, Clinical Pharmacology. Dr. Setnik will support INC Research’s world-class Early Phase Business Unit, providing scientific direction on matters related to abuse liability.
“We are delighted to welcome Beatrice to our clinical pharmacology team,” said Dr. Pierre Geoffroy, Vice President, Early Phase at INC Research. “Dr. Setnik’s extensive knowledge and experience in the area of human abuse liability assessment and risk evaluation, as well as in CNS drug development, clinical trial design and strategic lifecycle management, will be instrumental in furthering the development of our abuse potential capabilities and new scientific growth strategies for early phase clinical research.”
Dr. Setnik joins INC Research from Pfizer, most recently serving as Senior Director, Medical Development-Neuroscience, where she led clinical development, including abuse potential evaluation of several opioid formulations. Prior to Pfizer, she worked as a research scientist providing scientific input on specialty phase I-II clinical trials, including abuse potential studies.
Dr. Setnik chairs the clinical sub-team within the Cross Company Abuse Liability Consortium and has been an active member in the group since 2008. She also is an active participant in several congresses including the College on Problems of Drug Dependence. Dr. Setnik has been actively engaged in many aspects of abuse potential assessment, including development of patient reported outcome instruments and contributing to post-marketing surveillance studies. She earned her doctorate degree from the Pharmacology and Collaborative Program in Neuroscience at the University of Toronto and the Centre for Addiction and Mental Health.
Abuse Liability Studies at INC Research
INC Research has conducted more abuse liability studies than any other CRO. Its purpose-built facility in Toronto, Canada has the world’s largest database of recreational drug users, ensuring rapid enrollment, as well as an experienced staff, validated electronic data capture, secure on-site pharmacy, and rigorous quality control systems to ensure data meets the highest regulatory standards. For more information on INC Research’s early phase expertise and abuse liability capabilities, please visit our brochure and fact sheet.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to us for a complete range of customized Phase I to IV programs in all therapeutic areas and patient populations. Our Trusted Process® methodology and therapeutic foresight lead customers to better-informed product development decisions, while our solid site relationships are a critical success factor in delivering clinical trial results on time and on budget. INC was ranked "Top CRO" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.